CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $7,959,000 | -78.2% | 564,102 | -75.8% | 0.11% | -83.4% |
| Q3 2020 | $36,491,000 | -10.6% | 2,328,698 | 0.0% | 0.67% | -16.1% |
| Q2 2020 | $40,799,000 | +41.5% | 2,328,698 | +18.7% | 0.80% | -12.7% |
| Q1 2020 | $28,830,000 | -38.7% | 1,961,209 | +4.6% | 0.91% | -36.2% |
| Q4 2019 | $47,049,000 | +66.8% | 1,875,209 | 0.0% | 1.43% | -15.1% |
| Q3 2019 | $28,203,000 | -39.8% | 1,875,209 | 0.0% | 1.68% | -33.3% |
| Q2 2019 | $46,880,000 | +9.8% | 1,875,209 | 0.0% | 2.52% | +36.8% |
| Q1 2019 | $42,680,000 | -24.1% | 1,875,209 | 0.0% | 1.84% | -43.8% |
| Q4 2018 | $56,238,000 | +15.4% | 1,875,209 | +10.2% | 3.27% | +25.6% |
| Q3 2018 | $48,734,000 | – | 1,701,017 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |